Skip to main content
OpenTrials
Completed

NCT Number: NCT06264193

The Impact of Hypoxia on the Biochemical and Morphological Parameters of Blood in Rowers.

The response to hypoxia is very individual and depending on many aspects, such as the type of training, duration, intensity, or hypoxic stimulus, hypoxia affects the athlete in various ways. This multi-stage study investigated hematological and physiological responses to normobaric Live High-Train Low (LHTL) exposure in elite male rowers from the Polish national rowing team. Stage I evaluated responses during an 18-day LHTL intervention, whereas Stage II evaluated responses during a 14-day LHTL intervention and extended the assessment to 42 days after return to normoxia. The study focused particularly on hematological variables, erythropoietin (EPO), vascular endothelial growth factor (VEGF), and other physiological and biochemical responses associated with hypoxic exposure.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

About this study

I stage. The Polish national rowing team athletes, 13 males, were randomly divided into two groups:

  • The hypoxic group (H) included 8 rowers participating in sports training and the LHTL intervention, with progressive normobaric hypoxic exposure corresponding to simulated altitudes of 2000, 2500, and 3000 m.
  • The control group (C) consisted of 5 rowers participating only in sports training and living in normoxic rooms at the same sports camp. Rowers were observed during the preparatory period. The hypoxic group lived and slept in hypoxic rooms for at least 8-14 hours per day. During the camp, all rowers followed the same training schedule and diet. All participants' saturation and heart rate were measured daily, morning and evening, throughout the camp period. Venous blood samples were taken four times, at the beginning of the camp (Baseline), after 6 days, after 12 days, and after 18 days of the camp. Body composition parameters such as body mass index, body fat, and free fat mass were estimated using the bioelectrical impedance method of a Tanita BC 418 analyzer (Japan). Data analysis was performed using Statistica. The response to hypoxia is very individual. Depending on many factors, such as training type, duration, intensity, or hypoxic stimulus, hypoxia affects athletes in various ways. The results of this study have shown that the blood parameters did not increase significantly in the hypoxic group compared to the control group. However, reticulocytes, immature red blood cells, have shown significant differences after 18-d LHTL between groups. Further research should be carried out to investigate an optimal hypoxic dose and time, which will raise EPO, VEGF, and morphology variables.

II stage. Fourteen elite male rowers from the Polish national rowing team participated in the second stage and were randomly allocated to the LHTL group (n = 8) or the normoxic control group (n = 6). Both groups followed the same standardized training program. The LHTL intervention lasted 14 consecutive days and involved progressive normobaric hypoxic exposure corresponding to 2000-3000 m for approximately 14-16 h/day, while all training sessions were performed under normoxic conditions. Blood samples were collected at baseline, after 7 and 14 days of the intervention, and 8, 14, and 42 days after completion. Hematological variables, EPO, VEGF, iron-related indices, CK activity, and lipid-profile variables were assessed, while SpO₂ and resting HR were monitored throughout the intervention.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male national-team rowers aged ≥18 years.
  • Regular participation in rowing training.
  • Participation in the training camp.

Exclusion criteria

  • Exposure to hypoxic conditions or altitude above 1500 m within 1 month before the study.
  • Medical contraindications or adverse symptoms associated with hypoxic exposure.
  • Injury or health condition preventing participation in the training program.

Treatment and study plan

Normobaric hypoxia (LHTL)

Other

Participants lived in normobaric hypoxic rooms for 14-16 h per day while completing their regular training under normoxic conditions. The simulated altitude was progressively increased during the intervention.

Primary outcomes

  1. Erythropoietin (EPO) mlU/ml

    Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.

    immunoenzymatic assay methods using diagnostic kits

  2. Vascular endothelial growth factor (VEGF) mlU/ml

    Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.

    immunoenzymatic assay methods using diagnostic kits

Secondary outcomes

  1. Creatine kinase (CK) ng/ml

    Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.

    was determined using spectrophotometer analysis and diagnostic kits

  2. Hs C-Reactive Protein (hsCRP) mg/L

    Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention.

    was determined by immunoenzymatic assay methods using diagnostic kits

  3. Hemoglobin (Hb)g/dL

    Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.

    A professional accredited laboratory company determined the Hb level (Poland, ISO 9001:2008).

  4. Hematocrit (Htc)%

    Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.

    A professional accredited laboratory company determined the Htc level (Poland, ISO 9001:2008).

  5. Red blood cells (RBC)mln/mm3

    Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.

    A professional accredited laboratory company determined the RBC level (Poland, ISO 9001:2008).

  6. White blood cells (WBC)10 3/µL

    Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.

    A professional accredited laboratory company determined the WBC level (Poland, ISO 9001:2008).

  7. Reticulocytes (Ret)‰

    Time frame: Stage 1: at baseline and on days 6, 12, and 18 of the intervention. Stage 2: at baseline, on days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.

    A professional accredited laboratory company determined the Ret level (Poland, ISO 9001:2008).

  8. Peripheral oxygen saturation (SpO₂) (%)

    Time frame: Stage 1: daily from Day 1 through Day 18 of the intervention, in the morning after waking and in the evening before bedtime; Stage 2: daily from Day 1 through Day 14 of the intervention, in the morning after waking and in the evening before bedtime.

    Peripheral oxygen saturation (SpO₂) was measured non-invasively using a pulse oximeter (Tech-Med, ISO 13485). Measurements were performed twice daily, in the morning and evening, throughout each sports camp in both study groups.

  9. Heart rate (HR) (beats/min)

    Time frame: Stage 1: daily from Day 1 through Day 18 of the intervention; Stage 2: daily from Day 1 through Day 14 of the intervention.

    Heart rate (HR) was measured using a pulse oximeter (Tech-Med, ISO 13485). Measurements were performed twice daily, in the morning and evening, throughout each sports camp in both study groups.

Other outcomes

  1. Body mass (kg)

    Time frame: Stage 1: baseline and Days 6, 12, and 18 of the intervention; Stage 2: baseline and Days 7 and 14 of the intervention, and 8, 14, and 42 days after the intervention.

    Body mass was assessed using a multi-frequency bioelectrical impedance analyzer (TANITA MC-780MA). Measurements were performed between 7:00 and 7:30 a.m. on the same days as blood sampling.

  2. Body fat percentage (%)

    Time frame: Stage 1: baseline and Days 6, 12, and 18 of the intervention; Stage 2: baseline and Days 7 and 14 of the intervention, and 8, 14, and 42 days after the intervention.

    Body fat percentage was assessed using a multi-frequency bioelectrical impedance analyzer (TANITA MC-780MA). Measurements were performed between 7:00 and 7:30 a.m. on the same days as blood sampling.

  3. Fat mass (kg)

    Time frame: Stage 1: baseline and Days 6, 12, and 18 of the intervention; Stage 2: baseline and Days 7 and 14 of the intervention, and 8, 14, and 42 days after the intervention.

    Fat mass was assessed using a multi-frequency bioelectrical impedance analyzer (TANITA MC-780MA). Measurements were performed between 7:00 and 7:30 a.m. on the same days as blood sampling.

  4. Fat-free mass (kg)

    Time frame: Stage 1: baseline and Days 6, 12, and 18 of the intervention; Stage 2: baseline and Days 7 and 14 of the intervention, and 8, 14, and 42 days after the intervention.

    Fat-free mass was assessed using a multi-frequency bioelectrical impedance analyzer (TANITA MC-780MA). Measurements were performed between 7:00 and 7:30 a.m. on the same days as blood sampling.

  5. Total body water (kg)

    Time frame: Stage 1: at baseline and on Days 6, 12, and 18 of the intervention; Stage 2: at baseline, on Days 7 and 14 of the intervention, and at 8, 14, and 42 days after the intervention.

    Total body water was assessed using a multi-frequency bioelectrical impedance analyzer (TANITA MC-780MA). Measurements were performed between 7:00 and 7:30 a.m. on the same days as blood sampling.

Sponsors and collaborators

Lead sponsor

Poznan University of Physical Education

Other

Collaborators

  • The Polish Rowing Association, Warsaw, Poland.

Registry information

Official study title

The Effects of Live High-train Low on EPO, VEGF, and Hematological Variables in Elite Rowers

Acronym: IHOBMPBR

Important dates

Study start
2014
Primary completion
2015
Study completion
2015
First posted
Feb 16, 2024
Registry last updated
Sep 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.